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the CC BY-NC-ND license (http://creaAbstract Prostate cancers (PCa) have been reported to actively suppress antitumor immune
responses by creating an immune-suppressive microenvironment. There is mounting evidence
that PCas may undergo an ‘‘Epithelial Immune Cell-like Transition’’ (EIT) by expressing mole-
cules conventionally associated with immune cells (e.g., a variety of cytokines/receptors, im-
mune transcription factors, Ig motifs, and immune checkpoint molecules), which subsequently
results in the suppression of anti-cancer immune activity within the tumor microenvironment.
Recent progress within the field of immune therapy has underscored the importance of im-
mune checkpoint molecules in cancer development, thus leading to the development of novel
immunotherapeutic approaches. Here, we review the expression of select immune checkpoint
molecules in PCa epithelial and associated immune cells, with particular emphasis on clinical
data supporting the concept of an EIT-mediated phenotype in PCa. Furthermore, we summa-
rize current advances in anti-immune checkpoint therapies, and provide perspectives on their
potential applicability.
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Prostate cancer (PCa) is the most commonly-diagnosed non-
cutaneous cancer and the second leading cause of cancer-
related death in North American males. Although PCas
typically present as androgen-dependent cancers, and
initial androgen ablation can lead to substantial remissions,
they frequently return in an androgen-independent,
castration-resistant form. Within the last few years, a
number of new agents have been developed and approved
for treatment of metastatic castration-resistant prostate
cancer (mCRPC). These include second generation anti-
androgen agents (abiraterone acetate and enzalutamide),
cytotoxic drugs (cabazitaxel), and radiopharmaceuticals
(radium-223 dichloride) [1e4]. However, while these ad-
vancements have significantly improved patient survival
and quality of life, and slowed disease progression, relapse
invariably occurs. Therefore, there still remains an urgent
need for novel therapeutic targets and agents for mCRPC.
During the past decade, immune therapy has become
one of the most active and prolific areas of cancer
research. Sipuleucel-T, an autologous cellular immune
therapy, is the first therapeutic cancer vaccine and
currently the only FDA-approved immune therapy for PCa.
Recent advances have also underscored the crucial role of
immune checkpoint molecules in facilitating cancer devel-
opment, thus leading to numerous novel immunothera-
peutic approaches. In particular, studies have
demonstrated that PCa cells employ various mechanisms,
including the aberrant expression of immune checkpoint
molecules, in order to elude the immune system. There-
fore, these insights have served to provide corroborating
evidence for the “Epithelial Immune Cell-like Transition”
(EIT) hypothesis [5]. In this review, we will revisit the EIT
concept with regards to the expression of immune check-
point molecules on PCa cells, with an emphasis on clinical
data. Additionally, we will summarize current advances in
immune checkpoint-based therapies and provide perspec-
tives on their potential applicability.
2. EIT and PCa
Although the immune system plays an invaluable role in the
elimination of cancer cells, there is mounting evidence that
epithelial cancers avoid immune destruction by expressing
certain immune genes and products (e.g., cytokines and
immune-inhibitory molecules) not physiologically-
expressed by the originating normal tissues. On the basis
of these observations, we propose that the immune-
suppressive activity of epithelial cancers may arise from
acquired immune-suppressive characteristics via a trans-
differentiation process we term EIT. These properties could
enable cross-talk between cancer and immune cells,
thereby facilitating evasion of immune surveillance and co-
optation of immune mechanisms to promote tumor growth.
Recent reports have confirmed that PCa cells are able to
use various mechanisms in order to evade the immune
system (Fig. 1). Unsurprisingly, the presence of multiple
immunosuppressive cell types within the PCa microenvi-
ronment has been found to be associated with a poor
prognosis. In particular, an increased number of regulatoryT cells (the archetypal immunosuppressive cell type), have
been found within the peripheral blood of PCa patients
[6e8]. Furthermore, M2 macrophages and myeloid-derived
suppressor cells (MDSCs) also appear to be significant con-
tributors in maintaining the immunosuppressive microen-
vironment, with multiple reports associating increased
numbers with poor prognosis in PCa patients [9e12].
Conversely, the abundance of cytotoxic natural killer (NK)
cells within the PCa tumor could potentially confer a pro-
tective effect [13].
Mechanistically, several well-known immunosuppressive
molecules have been implicated in the inhibition of cyto-
toxic cell functions within the PCa microenvironment. For
example, the cytokine milieu of the prostate tumor was
found to contain high levels of TGF-b, and in conjunction
with decreased expression of activating receptors (NKp46
and NKG2D) and increased expression of the inhibitory re-
ceptor ILT2 on NK cell surfaces, suppress the cytotoxic
immune response against PCa cells [14]. Furthermore, high
levels of the NKG2D ligand have been found on the surfaces
of PCa-derived exosomes, resulting in the downregulation
of NKG2D on NK and CD8þ T cells, thus inhibiting their
activation [15]. Additionally, the upregulation of CSF1 and
IL1b in Pten-null prostatic epithelium have been shown to
facilitate the immunosuppressive effects of MDSCs, inhib-
iting T cell proliferation via high levels of arginase-1 and
iNOS expression [16].
Standard therapies used for the treatment of PCa have
also been found to induce immune suppression. In partic-
ular, upregulation of CSF1 following radiotherapy results in
an increased MDSC population in PCa patients. When a se-
lective inhibitor of CSF1R was administered in conjunction
with radiation, the treatment suppresses tumor growth
more effectively than with irradiation alone. This indicates
that an alleviation of the immunosuppressive tumor
microenvironment can enhance anticancer therapeutic ef-
fects [17]. Additionally, androgen deprivation therapy, the
current first-line treatment for metastatic PCa, has been
shown to mediate immune suppression via impairment of
initial T cell activation priming and IFN-g production [18].
Furthermore, although there have been reports suggesting
that concurrent immune therapy and castration could
initially enhance the number and function of cytotoxic
CD8þ T cells, the synergy is short lived and ultimately offset
by a parallel expansion of regulatory T cells [19].
Finally, the increased expression of immune checkpoint
molecules has also been observed in PCa, thus indicating an
important immune-suppressive mechanism underlying PCa
development. Below, we will focus on the details of
expression, function, and clinical applications of these
immune checkpoint molecules in PCa.
3. Immune checkpoint molecules and
PCa e expression and function
3.1. PD-1/PD-L1
First described by Ishida et al. in 1992 [20], programmed
death 1 (PD-1) is a transmembrane glycoprotein and T cell
co-inhibitory receptor expressed on T cells, B cells, NK
cells, dendritic cells (DCs), and activated monocytes [21].
Figure 1 Cross-talks between cancer and immune cells in the tumor microenvironment. Several anti-tumor immunities exist in
the tumor microenvironment, including activated tumor-specific T cells induced through tumor antigen presentation and T cell
receptor (TCR) recognition, natural killer (NK) cells and tumor-suppressing killer B cells. Cancer cells are able to use various
mechanisms to suppress the anti-tumor immunities, e.g., by increased expression of immune checkpoint proteins, release of
inhibitory cytokines, facilitation of immunosuppressive effects of tumor-infiltrating regulatory T cells and myeloid-derived sup-
pressor cells (MDSCs) and inhibition of the NK cell activations. The immunosuppressive activities of cancer cells, which may arise
from acquired immunosuppressive characteristics via a transdifferentiation process termed as “Epithelial Immune Cell-like Tran-
sition” (EIT), create a complex immunosuppressive network in the tumor microenvironment that facilitates evasion of immune
surveillance and co-optates immune mechanisms to promote tumor growth. APC, antigen-presenting cell.
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its ligand PD-L1 are part of co-inhibitory pathways that
serve to maintain peripheral tolerance by restricting the
lytic activity of immune cells [22]. The immediate conse-
quences of PD-1 stimulation are the inhibition of cytokine
secretion and immune cell proliferation [23].
PD-1/PD-L1 expression within cancer cells and the sur-
rounding microenvironment is observed to be a dynamic
process. Various immune checkpoint molecules, such as
PD-1, are up-regulated as T cells enter the tumor. This
induces the production of IFN-g, which results in the
up-regulation of PD-L1 [24]. High levels of PD-1 expression
have been demonstrated in both CD8þ prostate-infiltrating
T-lymphocytes and tumor-infiltrating regulatory T cells
[25,26].
Normally, PD-L1 expression is restricted to monocytes in
peripheral blood and macrophages in the lungs, liver, and
tonsils [27]. However, PD-L1 has been found to be highly
expressed in certain epithelial cancer cells and is correlated
with negative clinical outcomes, supporting the EIT hypoth-
esis [28]. Regarding PD-L1 expression on PCa cells, the evi-
dence remains mixed. Several studies have showed negative
staining of PD-L1 in mCRPC samples using immunohisto-
chemistry [29,30]. Martin et al. [31] also reported that PD-L1
is rarely expressed in primary PCas and independent of PTENloss. On the contrary, within a cohort of 16 mCRPC patients,
50% of patients showed PD-L1 expression on PCa cells (with
19% considered high-expressing) while 56% of patients had
tumor-infiltrating lymphocytes expressing PD-1 (with 19%
considered high-expressing) [32]. Finally, Gevensleben et al.
[33] recently evaluated PD-L1 expression using a new anti-
PD-L1 antibody in two independent cohorts including 873
primary radical prostatectomy specimens (derived from
treatment-naive patients) and demonstrated an increased
level of PD-L1 expression (52.2% and 61.7% in the respective
cohorts). This study also demonstrated that PD-L1 is an in-
dependent prognosticator of patients’ disease free survival.
3.2. B7-H3
The B7 family is comprised of proteins that interact with
receptors to modulate T-lymphocyte activity. Although
several members of the B7 family (including PD-L1, other-
wise known as B7-H1) have been well characterized, the
mechanisms of other B7 ligands (with regards to their
immune-stimulatory or immune-suppressive role) are still
not well understood [34].
First described in 2001 by Chapoval et al. [35], B7-H3 is a
type I transmembrane protein that has inducible expression
on several types of immune cells, such as T cells, dendritic
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varying levels of expression in the heart, liver, and prostate.
Although the precise receptor(s) have yet to be identified,
B7-H3 is thought to have different immune-modulatory ca-
pabilities (stimulatory or inhibitory) depending on the re-
ceptor. B7-H3 is able to exert immune stimulatory functions
by promoting T cell proliferation and expression of IFN-g,
while it is able to suppress immune responses by suppressing
cytokine production, type I T-helper (Th1) cell responses,
and NK cell-mediated cytolysis [34,36,37].
Numerous studies have found strong IHC staining of
B7-H3 in PCa samples (including adenocarcinomas, high-
grade prostatic intraepithelial neoplasias, and PCa cell
lines) [38e41]. From 823 prostatectomy samples, 93% were
found to have high levels of B7-H3 expression. These
elevated levels of B7-H3 were correlated with metastases
in addition to a higher risk of recurrence and death. Simi-
larly, other studies have shown that B7-H3 expression on
PCa cell surfaces correlate with aggressive histopatholog-
ical features (such as higher Gleason scores, increased
tumor volumes, extra-prostatic extensions, and infiltration
of seminal vesicles) [42], proliferation markers [42],
increased risk of tumor recurrence and progression
[40,42,43], and poor outcomes [40e43]. Finally, B7-H3
expression has also been found in samples of bone metas-
tases and hormone-resistant PCa [44].
3.3. B7-H4
B7-H4 is a type I transmembrane protein and is predomi-
nantly expressed on activated T cells, B cells, dendritic
cells, and monocytes. B7-H4 exerts several co-inhibitory
functions, such as inhibition of T cell proliferation and
cytokine production in CD4þ and CD8þ T cells [45e48].
Although its receptor(s) are yet to be determined, over-
expression of B7-H4 has been implicated in cancer cell
growth. Tumor expression of B7-H4 has been associated with
aggressive cancer features (increased neo-angiogenesis,
high tumor burden, and advanced tumor stage) and poor
clinical outcomes [48e50]. Notably, in both PCa and renal
cell carcinoma, robust expression of B7-H4 has been related
to metastatic disease, disease recurrence, and a higher risk
of death due to cancer [38,51]. A B7-H4 immunohisto-
chemical analysis conducted by Qian et al. found diffusely
positive cytoplasm and/or membrane staining in PCa sam-
ples to be correlated with higher tumor grades [52].
3.4. TIM-3
Monney et al. [53] first identified T cell immunoglobulin
mucin-3 (TIM-3) in 2002 as a negative immunomodulatory
molecule. TIM-3 acts in conjunction with its ligand,
galectin-9 (commonly up-regulated in various types of
cancers) [54], to negatively-regulate Th1 cell immunity,
induce peripheral tolerance, and cause the phagocytosis of
apoptotic cells [55]. Physiologically, Th1 cells and innate
immune cells (e.g., dendritic cells) express TIM-3 [56].
However, recent murine studies have found co-expression
of TIM-3 with PD-1 on tumor-specific CD8þ T cells, which
were able to significantly inhibit effector cytokine secre-
tion [54].TIM-3 also supports the progression of cancer by
contributing towards the immunosuppressive microenvi-
ronment via induction of T cell exhaustion [57e59]. Piao
et al. [60] recently reported increased expression of TIM-3
on both CD4þ and CD8þ T cells within peripheral blood and
PCa tissue specimens, with a strong correlation to charac-
teristics associated with advanced disease stage (metasta-
tic spread, prostate specific antigen (PSA) levels, and
Gleason score). A comparison of benign and cancer tissues
from 137 patients with treatment-naive PCa found an up-
regulation of TIM-3 in samples with prostatic intra-
epithelial neoplasia and invasive carcinomas [61].
3.5. LAG3
LAG3 (lymphocyte-activation gene 3) is an inhibitory re-
ceptor with a dual function [62]. LAG3 binds to HLA class II
molecules to inhibit T cell functions, particularly those of
CD8þ T cells. Additionally, LAG3 can strengthen the
immuno-inhibitory functions of T-regulatory cells. Elevated
expression of LAG3 has been found in tumor-infiltrating
antigen-presenting cells and macrophages. Further, LAG3
has been found to be upregulated in tumor cells [62].
However, this molecule remains under-evaluated with
regards to PCa.
3.6. CTLA-4
Considered a prototypical immune checkpoint, cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) is a co-inhibitory
receptor that restricts early-stage T cell activation [63,64].
Structurally homologous to CD28, CTLA-4 has markedly
higher affinity and avidity for the same ligands (B7-1 and
B7-2) as CD28 (the main receptor needed for T cell acti-
vation). Thus, binding of CTLA-4 effectively hijacks the
mechanisms that promote IL-2 mRNA production and cell
cycle progression [63e65].
Although CD28 is expressed by both naı¨ve and activated
T cells, CTLA-4 is expressed by activated CD8þ effector
T-cells and regulatory T cells (where interactions serve to
enhance regulatory T cell immunosuppressive activity)
[66]. However, unlike the previously described immune
checkpoint molecules, CTLA-4 is expressed exclusively by
T cells.
4. Targeting immune checkpoint molecules in
PCa
4.1. PD-1/PD-L1 blockade
Although PD-1/PD-L1 blockade therapies have shown
promising results in various types of cancers, the effect
of these therapies in PCa remains ambiguous. In a large
phase I trial for testing the safety and efficacy of nivolumab
(an anti-PD1 antibody) among 296 patients with advanced
solid tumors, no objective responses to single-agent PD-1
blockade were reported for any of the 17 PCa patients. This
lackluster response of PCa to PD-1 blockade may be
attributed to the phenotype of prostate-infiltrating lym-
phocytes, which are generally refractory to stimulation
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expression levels of PD-L1 in PCa cells, which were negative
in both samples examined by the study. However, the
sample size (for PCa) used in this study was too small to be
sufficiently indicative, particularly since only two of the 17
tissue specimens were available for immunohistochemical
staining. Therefore, further investigations into the role of
anti-PD-1/PD-L1 molecules for PCa treatment, especially in
larger cohorts, is necessary for determination of thera-
peutic efficacy.
Currently, there are a number of ongoing clinical trials
testing the safety and efficacy of PD-1/PD-L1 blockade
therapy as a single agent in PCa. In terms of PD-L1
blockade, a phase II trial for atezolizumab (a humanized
antibody against PD-L1) is currently underway for patients
with advanced solid tumors, including PCa (NCT02458638).
Furthermore, a number of phase I trials are also initiated
for anti-PD-L1 drugs (avelumab, nivolumab/MDX-1106)
alone or in combination with other therapies (MEDI4736
and olaparib/cediranib) in multiple tumor types, including
PCa (NCT01772004, NCT00730639, NCT02484404).
With regards to PD-1 blockade, pembrolizumab (an anti-
PD-1 antibody) is currently under evaluation as a single
agent for mCRPC patients previously-treated with enzalu-
tamide (NCT02312557). Concurrently, several other clinical
trials are assessing pembrolizumab in combination with
other therapies. These include pembrolizumab in
conjunction with cryosurgery (for treatment of patients
with newly diagnosed, oligo-metastatic PCa
[NCT02489357]), in combination with pTVG-HP plasmid DNA
vaccine (in mCRPC patients [NCT02499835]), and in com-
bination with ADXS31-142 (a Listeria monocyto-genes/PSA
[Lm-LLO-PSA] vaccine [ADXS-PSA]) in pre-treated mCRPC
patients (NCT02325557).
Finally, the effect of anti-PD-1 therapy in combination
with other immunotherapies, specifically within PCa, is also
under evaluation. A phase II trial of nivolumab and ipili-
mumab in AR-V7 positive mCRPC patients is assessing the
efficacy of concurrent PD-1 and CTLA-4 blockade
(NCT02601014). Additionally, another phase II trial is
assessing the effect of CT-011 (an anti-PD-1 antibody) in
combination with sipuleucel-T and cyclophosphamide in
advanced mCRPC patients (NCT01420965).
4.2. B7-H3 blockade
In a phase I dose-escalation study of enoblituzumab
(MGA271, an antibody targeting B7-H3) monotherapy, anti-
tumor activity was observed for several tumor types,
including patients with PCa, bladder cancer, and melanoma
[68]. Two phase I trials are ongoing in order to evaluate the
safety of enoblituzumab in combination with Keytruda
(pembrolizumab) and Yervoy (ipilimumab), respectively, in
patients with B7-H3-expressing cancers (NCT02475213,
NCT02381314).
4.3. CTLA-4 blockade
Even though CTLA-4 is expressed exclusively by T cells, it
remains one of the most well-characterized immune
checkpoint molecules. As such, CTLA-4 blockade therapiesare of particular significance. Notably, ipilimumab was the
first anti-immune checkpoint agent approved by the FDA to
treat cancer. It produced significant improvements in the
overall survival of metastatic melanoma patients [69,70].
Furthermore, a number of phase I and phase II trials have
evaluated the effect of ipilimumab (as a single agent or in
combination therapy) in mCRPC patients, and have
demonstrated some benefits associated with its clinical use
[71e74]. More recently, a phase III trial assessed the effi-
cacy of ipilimumab treatment following radiotherapy in
patients with mCRPC arising from docetaxel chemotherapy.
Ipilimumab was reported to significantly improve
progression-free survival and PSA response. Furthermore,
two other studies (phase III and phase II) have recently been
completed, the results of which are expected in 2016. The
first is a large, randomized phase III trial which examined
the efficacy of ipilimumab in mCRPC patients who have yet
to undergo chemotherapy (NCT01057810). The latter is a
neoadjuvant phase II trial, which tested ipilimumab in
combination with Lupron, in patients who have yet to un-
dergo radical prostatectomy (NCT01194271). Finally, other
combinatorial therapies of ipilimumab with other FDA-
approved agents are also under investigation. These
include two ongoing phase I/II trials evaluating the impact
of ipilimumab in combination with sipuleucel-T
(NCT01804465), and in combination with abiraterone ace-
tate plus prednisone (NCT01688492), in patients with PCa.
4.4. Other checkpoint molecules (i.e., TIM-3, LAG3
blockade)
The development of TIM-3 and LAG3 blockade therapy is in
its early stages. A phase I, first-in-human study of MBG453
(a TIM-3 inhibitor) has been designed to characterize the
safety, tolerability, and anti-tumor activity of MBG453, as a
single agent or in combination with PDR001, in patients
with advanced solid tumors, including PCa. Additionally,
another phase I trial is ongoing to assess the safety and
tolerability of BMS-986016 (an anti-LAG3 monoclonal anti-
body), alone and in combination with nivolumab, in sub-
jects with select advanced (metastatic and/or
unresectable) solid tumors.
5. Conclusions and further directions
There is an increasing body of evidence that supports the
hypothesis that an EIT-mediated immune-suppressive
microenvironment is a critical mechanism underlying the
development and progression/metastasis of PCa. Selective
targeting of this acquired immune-like phenotype, in
particular through certain aberrantly-expressed immune
checkpoint molecules, could likely lead to effective ther-
apeutic approaches. Although the blockade of CTLA-4 and
PD-1/PD-L1 have already demonstrated significant efficacy
in various types of cancers, ongoing clinical trials will
clarify its applicability towards PCa. Novel therapies, tar-
geting other immune checkpoint molecules, are currently
under evaluation in patients with various stages of PCa.
The success of immune checkpoint blockade as a mon-
otherapy likely requires a pre-existing antitumor immune
response in the patient. Some studies have shown various
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antitumor immunity. In view of this, the coupling of ther-
apies with immune therapy may enhance its overall effi-
cacy, on the basis of both inducing de novo antitumor
immune responses and alleviating the immune suppressive
environment through immune checkpoint blockade ther-
apy. In the future, further clinical trials evaluating combi-
natorial immune therapy or simultaneous blockade of
multiple immune checkpoint molecules, or immunother-
apies in combination with other therapies (such as
androgen ablation therapy, chemotherapy and radio-
therapy), will demonstrate potential synergistic effects.
Although this review has outlined a selection of well-
documented immune checkpoint molecules, immune
checkpoints are still a component of the overarching
immune-suppressive mechanism. Therefore, further in-
vestigations are necessary in order to clarify the full scope
of an EIT-mediated immune-suppressive phenotype, with
regards to the development of malignancies derived from
prostate and other epithelial origins. As such, an improved
understanding of the mechanisms underlying immune-
suppression and cancer development could provide valu-
able knowledge with which to inform the discovery of
additional therapeutic targets and agents.
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